The Process IS the Product
Good Manufacturing Practice for biologics rests on the principle that "the process is the product." Small changes in process or formulation can alter clinical outcomes. The Pfizer product commercially distributed (Process 2) was materially different from the product tested in clinical trials (Process 1).
43,538
Total Trial Participants
1.2%
Commercial Product Tested
Material Differences Between Processes
•
DNA Template Method: PCR (Process 1) vs. linearized plasmid DNA in E. coli (Process 2)
•
Purification Steps: Different procedures affecting final product purity
•
LNP Manufacturing: Large-scale commercial process differs from clinical-scale
!
Higher Adverse Events: Process 2 showed HIGHER adverse event rates in limited trial data
⚠️ The comparative analysis between Process 1 and Process 2 was abandoned in Protocol Amendment 20 (September 2022) due to "extensive usage" — AFTER hundreds of millions of doses were already administered.
AIP Criteria Satisfied
✓
System-wide manufacturing failures: Different products tested versus distributed
✓
Untrue statements of material fact: Presenting Process 1 data to support Process 2 approval
✓
Pattern of wrongful conduct: Systematic misrepresentation of product equivalency
Contamination Levels in Commercial Vials
Peer-reviewed publication entered into Congressional record shows systematic quality control failures in Process 2 manufacturing.
100×
Potential Underestimate
SV40 Promoter-Enhancer Sequences
SV40 (Simian Virus 40) sequences were detected but intentionally omitted from plasmid maps submitted to FDA, EMA, and Health Canada.
!
Nuclear Entry: SV40 sequences act as a "passport" helping genetic material cross into the cell nucleus, as Moderna explains in its own patent
!
Cancer Risk: Once in nucleus, contaminant DNA could integrate into human genome and activate cancer-causing genes
!
Intentional Edit: Removing SV40 from auto-generated plasmid maps required deliberate software editing — not accidental oversight
!
qPCR Flaws: Testing methods fundamentally flawed, potentially underestimating contamination 100-fold
⚠️ No genotoxicity studies were conducted on SV40 sequences despite regulatory requirements. This may explain rising rates of rapid-onset cancers.
AIP Criteria Satisfied
✓
System-wide manufacturing failures: Quality control failures across commercial production
✓
Untrue statements of material fact: Omission of SV40 sequences from regulatory submissions
✓
Pattern of wrongful conduct: Systematic concealment of contamination risks
Products Meet FDA Gene Therapy Definition
FDA defines gene therapy (July 2018 Guidance) as "products that mediate their effects by transcription and/or translation of transferred genetic material."
✓
Contains nucleic acids (modified mRNA) — MATCHES DEFINITION
✓
Administered to humans — MATCHES DEFINITION
✓
Mediates effect by translation (protein synthesis in human cells) — MATCHES DEFINITION
"Currently, mRNA is considered a gene therapy product by the FDA."
— Moderna 2020 SEC Filing (10-K)
Four Critical Regulatory Bypasses
1
Jurisdiction Manipulation: Routed to VRBPAC (vaccine committee) instead of CTGTAC (gene therapy committee) — gene therapy safety experts never consulted
2
Illegal Categorical Exclusions: Received exemptions from Environmental Assessment under 21 CFR 25.31 despite synthetic sequences not occurring naturally — renders BLA approvals "void ab initio"
3
No 15-Year Monitoring: Gene therapy products require 15-year follow-up for delayed malignancies, neurologic disorders, autoimmune conditions — none established
4
No Genotoxicity Studies: ICH S6(R1) requires studies for chromosomal integration, mutagenic potential, carcinogenic potential — never conducted
⚠️ Under 21 CFR 25.15(a), failure to submit adequate Environmental Assessments renders the BLA approvals legally invalid from inception (void ab initio).
AIP Criteria Satisfied
✓
Fraudulent application elements: Misrepresentation of fundamental product classification
✓
System-wide regulatory failures: Coordinated bypass of multiple regulatory frameworks
✓
Untrue statements of material fact: Concealment of gene therapy nature from regulators and public
Statistically Significant Imbalances
Analysis shows trial staff knew which participants received vaccine vs. placebo and treated them differently — compromising scientific validity of trial results.
43.5%
Vaccine Group Local PCR Tests
50.8%
Placebo Group Local PCR Tests
p<0.00001
Statistical Significance
Impact
Primary Endpoint Compromised
Protocol Deviation Imbalances
Chi-square analysis comparing treatment groups reveals systematic differential handling:
⚠️
"Nasal swab not collected": BNT162b2: 496 vs Placebo: 623 (p<0.001)
⚠️
"Urine pregnancy test not performed": BNT162b2: 383 vs Placebo: 522 (p<0.00001)
⚠️
Adverse event terms changed: BNT162b2: 207 vs Placebo: 97 (p<0.0001)
⚠️
Adverse events removed: BNT162b2: 153 vs Placebo: 103 (p<0.01)
⚠️ The primary endpoint of trial C4591001 was laboratory-confirmed COVID-19 cases. Differential PCR testing rates directly inflate apparent vaccine efficacy by detecting more cases in the placebo group.
AIP Criteria Satisfied
✓
Pattern of wrongful conduct: Statistical evidence demonstrates systematic rather than random deviations
✓
Data reliability questions: Compromised blinding undermines fundamental trial validity
✓
Material fact implications: Trial integrity is material to efficacy and safety determinations
Subject 11141050 — Sudden Cardiac Death
Oct 19, 2020
Subject died — Sudden cardiac death (26 days BEFORE data cutoff)
Nov 14, 2020
EUA data cutoff date — death should have been included
Nov 25, 2020
Death finally entered — 37 days after death (protocol requires 24-hour reporting)
Dec 10, 2020
FDA VRBPAC meeting — death NOT disclosed
Subject 11201050 — Cardiac Arrest
Nov 7, 2020
Subject died — Cardiac arrest, 72 days after Dose 2 (7 days BEFORE data cutoff)
Nov 7, 2020
Husband notified clinical site same day — Pfizer documented receipt of notification
Nov 14, 2020
EUA data cutoff date — death should have been included
Dec 10, 2020
FDA VRBPAC meeting — death NOT disclosed to advisory committee
⚠️ The December 2020 NEJM article (Polack et al.) and FDA VRBPAC briefing reported only TWO deaths in BNT162b2 arm. These two concealed cardiac deaths would have changed the ratio from 2:4 to 4:4 — material to risk-benefit assessment.
Missing Subjects & Dataset Manipulation
301
Missing Randomization Numbers
1,203
Subject Count Reduction EUA→BLA
⚠️ August 21, 2020 was the same day whistleblower Augusto Roux (participant #12312978) experienced severe adverse effects including pericarditis. Criminal investigations ongoing in Argentina.
AIP Criteria Satisfied
✓
Untrue statements of material fact: Omission of known material safety information
✓
Pattern of wrongful conduct: Systematic exclusion of safety-relevant data
✓
Fraudulent application elements: Concealment of information material to risk-benefit assessment
✓
System-wide data integrity failures: Pattern spans multiple database systems and timeframes